Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Neuro-Oncology|July 16, 2025
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastasesTia Cheunkarndee, Zsombor Ritter, Max Saint-Germain, et al.Clinical Lung Cancer|April 30, 2019
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung CancerKhinh Ranh Voong, Sarah Z Hazell, Wei Fu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2018
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint ImmunotherapyKarthik Suresh, Kevin J Psoter, Khinh Ranh Voong, et al.Oncology and Therapy|July 22, 2024
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with ImmunotherapyRyan D Gentzler, John Guittar, Akash Mitra, et al.JTO Clinical and Research Reports|November 8, 2021
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLCJoshua E Reuss, Emily Brigham, Kevin J Psoter, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk FactorsKarthik Suresh, Khinh Ranh Voong, Bairavi Shankar, et al.Cancers|November 9, 2024
Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and ImmunotherapyFyza Y Shaikh, Seoho Lee, James R White, et al.The Journal of Clinical Investigation|July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitisKarthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.Pageof 6